Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).

The pharmacogenomics journal - 1 Feb 2007

Roses A D, Saunders A M, Huang Y, Strum J, Weisgraber K H, Mahley R W

Abstract excerpt

Safety and efficacy pharmacogenetics can be applied successfully to the drug discovery and development pipeline at multiple phases. We review drug-target screening using high throughput SNP associations with complex diseases testing more than 1,800 candidate targets with approximately 7,000 SNPs. Alzheimer's disease data are provided as an example. The supplementation of target-selected screening with genome-wide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Industry

Share to Drug-Related Side Effects and Adverse Reactions

Share to Genome, Human

Share to Pharmacogenetics

Share to Rosiglitazone

Share to Thiazolidinediones

Source

Identifiers

PMID: 16770341
DOI: 10.1038/sj.tpj.6500397

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).PMID 16770341Read ↗

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.Semantic proximity Read ↗

Pharmacogenetic Basis for Therapeutic Optimization in Alzheimer’s DiseaseSemantic proximity Read ↗

Opportunities in pharmacogenomics for the treatment of Alzheimer’s diseaseSemantic proximity Read ↗

Pharmacogenomics and treatment for dementia induced by Alzheimer's disease.Semantic proximity Read ↗

Pharmacogenomics for the treatment of dementia.Semantic proximity Read ↗

Influence of pharmacogenetic factors on Alzheimer's disease therapeutics.Semantic proximity Read ↗

The druggable genome and support for target identification and validation in drug developmentSemantic proximity Read ↗

Pharmacogenetic Considerations in the Treatment of Alzheimer’s DiseaseSemantic proximity Read ↗

Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer’s DiseaseSemantic proximity Read ↗

Re-thinking Alzheimer's disease therapeutic targets using gene-based testsSemantic proximity Read ↗

Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.Semantic proximity Read ↗

The Alzheimer’s disease drug development landscapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.